Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success
Bristol Myers Squibb (BMS) and Tempus AI have expanded their strategic collaboration with a new initiative focused on using AI and multimodal real‑world data to optimize clinical trial design and execution.
The collaboration initially covers five clinical trial programs and aims to improve the Probability of Technical & Regulatory Success (PTRS), effectively increasing the likelihood that drug candidates will succeed in development and gain approval.
Tempus’ AI-enabled Lens platform will analyze a large library of de‑identified multimodal patient records (including clinical, molecular/genomic, and other data) to identify patient subgroups most likely to benefit from investigational therapies.
The work spans oncology and neuroscience, including solid tumors such as lung, colon, and prostate cancers, as well as Alzheimer’s disease drug development, demonstrating cross‑therapeutic use of Tempus’ data assets.
This expanded initiative builds on an existing BMS–Tempus relationship, including the Next Pathways program deployed across 13 community health systems to identify and close care gaps for patients with advanced non‑small cell lung cancer (aNSCLC).
By improving trial design and patient selection, the partners aim to reduce late‑stage trial failures and increase the efficiency and speed of clinical development across BMS’s pipeline.